Cited by 204SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

Open access

Nguyen-Contant, Phuong, Embong, A. Karim, Kanagaiah, Preshetha, Chaves, Francisco A., Yang, Hongmei, Branche, Angela R., Topham, David J., Sangster, Mark Y.·2020·mBio

DOI 10.1128/mbio.01991-20PMC PMC7520599

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/mbio.01991-20

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769

Flagged first, then by citations

Show all 35 references

Sorted by citations

Items 101–200 of 204

IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes
Garrido, J. L. V., Medina, M. A., Bravo, F., McGee, S., Fuentes‐Villalobos, F., Calvo, M. A., Pinos, Y., Bowman, J. W., Bahl, C. D., Barría, M. I., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110904 · Cited by 13
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
Bellusci, L., Grubbs, G., Sait, S., Yonker, L. M., Randolph, A. G., Novak, T., Kobayashi, T., Overcoming COVID−19 Investigators, & Khurana, S. (2023) · Nature Communications · doi:10.1038/s41467-023-43152-y · Cited by 12
Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases
Deakin, C. T., Cornish, G. H., Ng, K. W., Faulkner, N., Bolland, W., Hope, J., Rosa, A., Harvey, R., Hussain, S., Earl, C. P., et al. (2021) · Med · doi:10.1016/j.medj.2021.08.001 · Cited by 12
Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France
Zedan, H. T., & Nasrallah, G. K. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103580 · Cited by 12
Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
Zhou, D., Zhou, R., & Chen, Z. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab027 · Cited by 12
Broad Cross-Reactive IgA and IgG against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection
Wang, J., Young, B. E., Li, D., Seppo, A., Zhou, Q., Wiltse, A., Nowak-Wegrzyn, A. H., Murphy, K., Widrick, K., Diaz, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10060980 · Cited by 12
Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection
Kobayashi, K., Tachibana, M., & Tsutsumi, Y. (2021) · Innate Immunity · doi:10.1177/17534259211043159 · Cited by 11
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19Preprint
Kapłonek, P., Wang, C., Bartsch, Y. C., Fischinger, S., Gorman, M. J., Bowman, K. A., Kang, J., Dayal, D., Martin, P., Nowak, R. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.11.443609 · Cited by 12
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Abela, I. A., Schwarzmüller, M., Ulytė, A., Radtke, T., Haile, S. R., Ammann, P., Raineri, A., Rueegg, S., Epp, S., Berger, C., et al. (2024) · mBio · doi:10.1128/mbio.02722-23 · Cited by 10
Could Antigen Presenting Cells Represent a Protective Element during SARS-CoV-2 Infection in Children?
Lauro, R., Irrera, N., Eid, A. H., & Bitto, A. (2021) · Pathogens · doi:10.3390/pathogens10040476 · Cited by 12
Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama
Guardia, C. D. L., Rangel, G. A., Villarreal, A. E., Goodridge, A., Fernández, P. L., & Lleonart, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257351 · Cited by 12
Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic
Wang, G., Xiang, Z., Wang, W., & Chen, Z. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200049 · Cited by 12
Microfluidics combined with electron microscopy for rapid and high-throughput mapping of antibody–viral glycoprotein complexes
Sewall, L. M., Rocha, R. D. P. F., Gibson, G., Louie, M., Xie, Z., Bangaru, S., Tran, A. S., Ozorowski, G., Mohanty, S., Beutler, N., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01411-x · Cited by 11
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 9
Humoral Immune Response Profile of COVID-19 Reveals Severity and Variant-Specific Epitopes: Lessons from SARS-CoV-2 Peptide Microarray
Acharjee, A., Ray, A., Salkar, A., Bihani, S., Tuckley, C., Shastri, J. S., Agrawal, S. R., Duttagupta, S. P., & Srivastava, S. (2023) · Viruses · doi:10.3390/v15010248 · Cited by 10
A FluoroSpot B assay for the detection of IgA and IgG SARS-CoV-2 spike-specific memory B cells: Optimization and qualification for use in COVID-19 vaccine trials
Bisceglia, H., Barrier, J., Ruiz, J., & Pagnon, A. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113457 · Cited by 8
Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas
Traoré, A., Guindo, M. A., Konate, D. S., Traoré, B., Diakité, S. A. S., Kanté, S., Dembélé, A., Cissé, A., Incandela, N. C., Kodio, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856033 · Cited by 10
Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study
Domènech-Montoliu, S., Puig‐Barberà, J., Pac-Sa, M. R., Vidal-Utrillas, P., Latorre-Poveda, M., Rio-González, A. D., Ferrando-Rubert, S., Ferrer-Abad, G., Sanchéz-Urbano, M., Aparisi-Esteve, L., et al. (2021) · COVID · doi:10.3390/covid1010006 · Cited by 8
Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19)
Lee, J., Lee, D., Jung, J. H., Ryu, J. H., Shin, S., Cho, S., Lee, R., & Oh, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038712 · Cited by 9
Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
Martín, M. C., Jimenez, A., Ortega, N., Parrado, A., Page, I., Gonzalez, M., & Blanco-Peris, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264124 · Cited by 9
Association between IgG responses against the nucleocapsid proteins of alphacoronaviruses and COVID-19 severity
Nückel, J., Planatscher, E., Mohr, A., Deichl, K., Mijočević, H., Feuerherd, M., Wolff, L. S., Erber, J., Schneider, J., Quante, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889836 · Cited by 9
Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand
Li, Y., Merbah, M., Wollen-Roberts, S. E., Beckman, B., Mdluli, T., Swafford, I., Mayer, S. V., King, J., Corbitt, C., Currier, J. R., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2811.221041 · Cited by 9
Coronavirus spike protein-specific antibodies indicate frequent infections and reinfections in infancy and among BNT162b2-vaccinated healthcare workers
Kolehmainen, P., Huttunen, M., Iakubovskaia, A., Maljanen, S., Tauriainen, S., Yatkin, E., Pasternack, A. H., Naves, R. A., Toivonen, L., Tähtinen, P. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35471-3 · Cited by 12
Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic
Li, X., Zhang, Y., He, L., Si, J., Qiu, S., He, Y., Wei, J., Wang, Z., Xie, L., Li, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66369 · Cited by 8
Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice
Cervantes‐Torres, J. B., Cabello-Gutiérrez, C., Ayón‐Núñez, D. A., Soldevila, G., Olguín‐Alor, R., Díaz, G., Acero, G., Segura‐Velázquez, R. A., Huerta, L., Gracia‐Mora, I., et al. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12927-0 · Cited by 7
SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination
Teng, S., Hu, Y., Wang, Y., Tang, Y., Wu, Q., Zheng, X., Lü, R., Pan, D., Liu, F., Xie, T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355949 · Cited by 8
Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
Jayathilaka, D., Jeewandara, C., Gomes, L., Jayadas, T. T. P., Kamaladasa, A., Somathilake, G., Guruge, D., Pushpakumara, P. D., Ranasinghe, T., Aberathna, I. S., et al. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac009 · Cited by 9
A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA
Rachman, A., Iriani, A., Sukrisman, L., Rajabto, W., Mulansari, N. A., Lubis, A. M., Cahyanur, R., Prasetyawaty, F., Priantono, D., Rumondor, B. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281907 · Cited by 8
SARS-CoV-2 (Covid-19): A short update on molecular biochemistry, pathology, diagnosis and therapeutic strategies
Ismail, A. A. (2021) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563221992390 · Cited by 6
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
Gao, X., Fan, L., Zheng, B., Li, H., Wang, J., Zhang, L., Li, J., & Zhu, F. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2055373 · Cited by 8
Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort
Zhu, L., Mao, N., Yi, C., Simayi, A., Feng, J., Feng, Y., He, M. Y., Ding, S., Wang, Y., Wang, Y., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2146535 · Cited by 7
Superior possibilities and upcoming horizons for nanoscience in COVID-19: noteworthy approach for effective diagnostics and management of SARS-CoV-2 outbreak
Bhattacharjee, B., Ikbal, A. M. A., Farooqui, A., Sahu, R. K., Ruhi, S., Syed, A., Miatmoko, A., Khan, D., & Khan, J. (2023) · Chemical Papers · doi:10.1007/s11696-023-02795-3 · Cited by 7
SARS-CoV-2 Antibody Testing: Where Are We Now?
Smerczak, E. (2021) · Laboratory Medicine · doi:10.1093/labmed/lmab061 · Cited by 8
A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?
Trombetta, C. M., Marchi, S., Viviani, S., Manenti, A., Casa, E., Dapporto, F., Remarque, E. J., Bollati, V., Manini, I., Lazzeri, G., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2047582 · Cited by 8
A critical review on heat and mass transfer modelling of viral infection and virion evolution: The case of SARS-CoV2
Trancossi, M., Pascoa, J. C., & Sharma, S. (2021) · Thermal Science · doi:10.2298/tsci210614215t · Cited by 7
Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19Preprint
Herman, J. D., Atyeo, C. G., Zur, Y., Cook, C., Patel, N. J., Vanni, K. M. M., Kowalski, E. N., Qian, G., Shadick, N. A., Laffenburger, D., et al. (2022) · medRxiv · doi:10.1101/2022.09.25.22280335 · Cited by 7
Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate
Toapanta, F. R., Hu, J., Meron-Sudai, S., Mulard, L. A., Phalipon, A., Cohen, D., & Sztein, M. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291664 · Cited by 6
Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones
Mutsaerts, E. A. M. L., van Cranenbroek, B., Madhi, S. A., Simonetti, E., Arns, A. J., Jose, L., Koen, A. L., van Herwaarden, A. E., de Jonge, M. I., & Verhagen, L. M. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.034 · Cited by 6
Exposure to avian coronavirus vaccines is associated with increased levels of SARS‐CoV ‐2‐cross‐reactive antibodies
Ardıçlı, Ö., Çarlı, K. T., Satitsuksanoa, P., Dreher, A., Cusini, A., Hutter, S., Mirer, D., Rückert, B., Jónsdóttir, H. R., Weber, B., et al. (2022) · Allergy · doi:10.1111/all.15441 · Cited by 6
Passive Immunity Should and Will Work for COVID-19 for Some Patients
Cimolai, N. (2021) · Clinical Hematology International · doi:10.2991/chi.k.210328.001 · Cited by 7
Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cTFH cells
García-Jiménez, Á. F., Cáceres-Martell, Y., Fernández‐Soto, D., Martínez‐Fleta, P., Casasnovas, J. M., Sánchez‐Madrid, F., Frade, J. M. R., Valés‐Gómez, M., & Reyburn, H. T. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.4covcra0721-356rrr · Cited by 6
Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol
Muñoz, F. M., Beigi, R. H., Posavad, C. M., Richardson, B. A., Chu, H. Y., Bok, K., Campbell, J. D., Cardemil, C. V., DeFranco, E., Frenck, R. W., et al. (2022) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-022-04500-w · Cited by 6
Rise in broadly cross-reactive adaptive immunity against human β-coronaviruses in MERS-recovered patients during the COVID-19 pandemic
Kim, S.-J., Kim, Y., Jeon, S., Park, U., Kang, J.-I., Jeon, K., Kim, H. R., Oh, S., Rhee, J.-Y., Choi, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk6425 · Cited by 6
Assessment of the cellular immunity response to the new coronavirus infection COVID-19
Lobov, A. V., Ivanova, P. I., Pogodina, E. A., Kazey, V. I., Maksimova, E. D., & Shubina, I. Z. (2021) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2021-20-4-10-17 · Cited by 5
The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2
Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5
Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus
Gulova, S. M., Veselkina, U. S., & Astrakhantseva, I. V. (2025) · Vaccines · doi:10.3390/vaccines13070761 · Cited by 6
Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19
Chen, L., Pang, P., Qi, H., Yan, K., Ren, Y., Ma, M., Cao, R., Li, H., Hu, C., Li, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770982 · Cited by 5
Serological Assessment of COVID-19 Patients in Brazil: Levels, Avidity, and Subclasses of IgG Against RBDPreprint
Moura, A., da Costa, H. H. M., Correa, V. A., Lima, A. K. S., Lindoso, J. Â. L., Gaspari, E. D., Hong, M. A., Cunha-Junior, J. P., & Prudêncio, C. R. (2021) · Research Square · doi:10.21203/rs.3.rs-131195/v1 · Cited by 5
Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals
Adami, F. L., de Castro, M. V., Almeida, B. D. S., Daher, I. P., Yamamoto, M. M., Santos, K. S., Zatz, M., Naslavsky, M. S., Rosa, D. S., Cunha‐Neto, E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396603 · Cited by 4
Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach
Weskamm, L. M., Tarnow, P., Harms, C., Huchon, M., Raadsen, M. P., Friedrich, M., Rübenacker, L., Grüttner, C., García, M. G., Koch, T., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110470 · Cited by 4
Ni/Fe‐MOF Electrochemical Transistor Biosensors with 3D Debye Space for Ultrasensitive Detection of Coronavirus Nucleocapsid Protein
Tan, P., Shen, S., Zheng, Y., Tang, Y., Luo, Y., Zhang, Z., Men, D., & Duan, G. (2025) · Small · doi:10.1002/smll.202407709 · Cited by 4
Systemic and mucosal immune signatures of protection against SARS-CoV-2 transmission in humans
Rojo-Fernandez, A., Aslam, S., Alam, F., Escalera, A., Villamandos, V., Caton, B., Megías, G., Gonzalez, A., Buzón, L., Ayllón, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102505 · Cited by 5
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity
Stanley, A. M., Aksyuk, A. A., Wilkins, D. E., Green, J. A., Lan, D., Shoemaker, K., Tieu, H., Sobieszczyk, M. E., Falsey, A. R., & Kelly, E. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401728 · Cited by 4
Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)
Zhang, T., Yang, D., Tang, L., & Hu, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13272 · Cited by 5
Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice
Germanó, M. J., Giai, C., Cargnelutti, D. E., Colombo, M. I., Blanco, S., Konigheim, B. S., Spinsanti, L., Aguilar, J., Gallego, S. V., Valdez, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28584 · Cited by 5
To be remembered: B cell memory response against SARS‐CoV ‐2 and its variants in vaccinated and unvaccinated individuals
Ahmed, N., Athavale, A., Tripathi, A. H., Subramaniam, A., Upadhyay, S. K., Pandey, A. K., Rai, R. C., & Awasthi, A. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13345 · Cited by 4
What could be the potential reasons for relatively low coronavirus disease 2019 (COVID-19) fatality rates in Africa? The case for Ethiopia
Zerfu, T. A., & Tareke, A. A. (2021) · Journal of Global Health · doi:10.7189/jogh.11.03057 · Cited by 4
Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka
Jeewandara, C., Guruge, D., Pushpakumara, P. D., Kamaladasa, A., Aberathna, I. S., Ramu, S. T., Gunasekera, B., Wijesinghe, A., Dissanayake, O., Kuruppu, H., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100762 · Cited by 4
Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals
Embong, A. K., Nguyen, P. Q. T., Wang, J., Kanagaiah, P., Chaves, F. A., Fitzgerald, T. F., Zhou, Q., Kosoy, G., Branche, A. R., Miller, B. L., et al. (2022) · Pathogens · doi:10.3390/pathogens11020186 · Cited by 4
Self-citation
Severe Acute Respiratory Syndrome Coronavirus 2 Cross-Reactive B and T Cell Responses in Kidney Transplant Patients
Paniskaki, K., Anft, M., Thieme, C. J., Skrzypczyk, S., Konik, M., Dolff, S., Westhoff, T. H., Nienen, M., Stittrich, A., Stervbo, U., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.016 · Cited by 4
Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein
Ert, H. A. V., Bohan, D., Rogers, K. J., Fili, M., Chávez, R. A. R., Qing, E., Han, C., Dempewolf, S., Hu, G., Schwery, N., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02676-21 · Cited by 3
Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants
Shamabadi, N. S., Bagasra, A. B., Pawar, S., & Bagasra, O. (2023) · Libyan Journal of Medicine · doi:10.1080/19932820.2023.2209949 · Cited by 3
Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease
Monteiro, A., Chang, A. J., Welliver, R. R., Baron, S. W., & Hicar, M. D. (2022) · Virology · doi:10.1016/j.virol.2022.08.010 · Cited by 3
Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2
Huang, X., Liang, C., Li, M., Chen, H., Li, Z., Ruan, Q., Hu, X., Zeng, L., Lin, H., Zhao, W., et al. (2023) · Vaccines · doi:10.3390/vaccines11010123 · Cited by 4
Update to COVID-19 serologic testing : FAQs and caveats
Kadkhoda, K. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.20054-up · Cited by 3
COVID-19 and the Unraveling of Experimental Medicine - Part II
Thorp, K. E., & Thorp, J. A. (2022) · The Gazette of Medical Sciences · doi:10.46766/thegms.pubheal.22022804 · Cited by 3
Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses
Mihăescu, G., Chifiriuc, M. C., Vrâncianu, C. O., Constantin, M., Filip, R., Popescu, M. R., Burlibaşa, L., Nicoară, A. C., Bolocan, A., Iliescu, C., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9122578 · Cited by 3
Characterization of SARS-CoV-2 Convalescent Patients’ Serological Repertoire Reveals High Prevalence of Iso–RBD AntibodiesPreprint
Curtis, N. C., Shin, S., Hederman, A. P., Connor, R. I., Wieland‐Alter, W., Ionov, S., Boylston, J. A., Rose, J., Sakharkar, M., Dorman, D. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.08.556349 · Cited by 4
SERS Detection of SARS‐CoV‐2 Spike Proteins and IgG Antibodies Using Metallic H ‐type Nano‐Apertures
Gao, Y., Jiang, Z., Ioannou, N. K., & Kotsifaki, D. G. (2025) · Advanced Physics Research · doi:10.1002/apxr.202500143 · Cited by 2
Detection of IgA and IgG Antibodies against the Structural Proteins of SARS-CoV-2 in Breast Milk and Serum Samples Derived from Breastfeeding Mothers
Cortés-Sarabia, K., Guzman-Silva, V., Martinez-Pacheco, K. M., Meza-Hernández, J. A., Luna-Pineda, V. M., Leyva‐Vázquez, M. A., Vences-Velázquez, A., Beltrán‐Anaya, F. O., Moral-Hernández, Ó. D., & Illades‐Aguiar, B. (2023) · Viruses · doi:10.3390/v15040966 · Cited by 2
Author response: Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Grobben, M., van der Straten, K., Brouwer, P. J. M., Brinkkemper, M., Maisonnasse, P., Dereuddre‐Bosquet, N., Appelman, B., Lavell, A. A., van Vught, L. A., Burger, J. A., et al. (2021) · eLife · doi:10.7554/elife.70330.sa2 · Cited by 2
Immunology of coronavirus disease 2019 raises more questions than answers
Nasr, A. (2021) · Saudi Journal for Health Sciences · doi:10.4103/sjhs.sjhs_168_20 · Cited by 1
In-house assays for detecting anti-SARS-CoV-2 antibodies in serum and urine: Correlation with COVID-19 severity from a cohort study in Qatar
Vaikath, N. N., Al‐Nesf, M. A., Majbour, N. K., Abdesselem, H., Gupta, V., Bensmail, I., Abdi, I. Y., Elmagarmid, K. A., Shabani, S., Sudhakaran, I. P., et al. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102744 · Cited by 1
High CD4⁺ T-cell responses in seronegative individuals following SARS-CoV-2 exposure during a dormitory outbreak
Teng, O., Quek, A. M. L., Ooi, D. S. Q., Wang, S., Fragata, L., Ng, I. X. Q., Cui, J., Chen, J., Hartman, M., Hutchinson, P. E., et al. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108024 · Cited by 1
Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses
Zhang, B., Liu, Y., Chen, T., Lai, J., Liu, S., Liu, X., Zhu, Y., Rao, H., Peng, H., & Ma, X. (2025) · Vaccines · doi:10.3390/vaccines13111168 · Cited by 2
ASSESSMENT OF SARS-COV-2 SPECIFIC B-CELL IMMUNE MEMORY: EVIDENCE FOR PERSISTENCE UP TO 1 YEAR POST-INFECTION
Bozhkova, M., Kalfova, T., Petrov, S., Velyanova, T., Taskov, H. B., Nikolova, M. H., & Murdjeva, M. (2023) · PROBLEMS of Infectious and Parasitic Diseases · doi:10.58395/wc1f1t22 · Cited by 1
COVID-19 humoral response
Tworek, A., Rydzewski, A., Rydzewska, G. M., Głuszek–Osuch, M., & Lewandowski, K. (2023) · Medical Studies · doi:10.5114/ms.2023.131679 · Cited by 2
Arrayed Imaging Reflectometry monitoring of anti-viral antibody production throughout vaccination and breakthrough Covid-19
Klose, A. M., Kosoy, G., & Miller, B. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0277846 · Cited by 2
Structural and Computational Design of a SARS-2 Spike Antigen with Increased Receptor Binding Domain Exposure and Improved ImmunogenicityPreprint
Williams, J. A., Biancucci, M., Lessen, L. N., Tian, S., Balsaraf, A., Chen, L., Chesterman, C. C., Maruggi, G., Vandepaer, S., Huang, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.29.518231 · Cited by 1
Answer to Paredes et al. commenting on “COVID-19 vaccines under the International Health Regulations — We must use the WHO International Certificate of Vaccination or Prophylaxis”
Petersen, E., Lucey, D. R., Blumberg, L. H., Kramer, L. D., Al-Abri, S., Lee, S. S., Pinto, T. C. A., Obiero, C. W., Rodriguez-Morales, A. J., Yapi, R. B., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.076
Humoral immune responses against seasonal coronaviruses predict efficiency of SARS-CoV-2 spike targeting, FcγR activation, and corresponding COVID-19 disease severityPreprint
Garrido, J. L., Medina, M. A., Bravo, F., McGee, S., Fuentes, F., Calvo, M., Bowman, J., Bahl, C., Barria, M. I., Brachman, R. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.14.460338
TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO)
Martinón‐Torres, F., García‐Sastre, A., Pollard, A. J., Martı́n, C., Osterhaus, A. D. M. E., Ladhani, S. N., Ramilo, O., Rial, J. G., Salas, A., Bosch, F. X., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1953351
COVID-19 Vaccines Confer a Prophylactic Effect on Common Cold
Otieno, F. O., & Walekhwa, M. N. (2021) · Kabarak journal of research and innovation. · doi:10.58216/kjri.v11i3.76
Review 2: "Durable SARS-CoV-2 B cell immunity after mild or severe disease"
Sangster, M. Y. (2021) · doi:10.1162/2e3983f5.40346d73
Self-citation
Seric IgG anti-SARS-CoV-2 pre- and post- Covid-19 pandemic from Mexican asymptomatic subjects
Aguirre‐Cruz, L., Guzmán-García, M., Acosta, I., de la Cruz-Aguilera, D. L., Landero-Isidro, I., Pérez-González, J. P., Chávez-Duarte, J., & Leyva-Rendón, A. (2022) · Salud Pública de México · doi:10.21149/12930
Seroprevalence Surgery of Anti-SARS-CoV-2 Antibodies Based on COVID-19 Vaccine Type in Academy Community, East Kalimantan, Indonesia
Paramita, S., Khotimah, S., Marwan, M., Isnuwardana, R., Fitriany, E., & Nufus, A. Z. S. Z. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.9957
Imunomodulação da expressão de PD-1 em monócitos e linfócitos T e B na infecção por SARS-CoV-2
Beserra, D. R. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-16022023-122405
Spectrum of Biochemical Alterations in Patients with Covid-19
Chaudari, Z. K., Muhammad, Y., Sarfraz, M., Butt, M. T., Jadoon, M., & Shoukat, S. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023172452
Emerging Pandemic Infectious Disease Threats
Corry, D. B., Hotez, P. J., Bottazzi, M. E., Weatherhead, J. E., Maresso, A. W., Heckmann, E., & Bimler, L. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00031-9
The Influence of Pre-Existing Immunity against Human Common Cold Coronaviruses on COVID-19 Susceptibility and Severity
Tarazona, E. D. L. T., Jiménez, D., Marcos-Mencía, D., Mendieta-Baro, A., Rivera-Delgado, A., Romero‐Hernández, B., Muriel, A., Rodríguez-Domínguez, M., Villar, S. S., & Moreno, S. (2023) · Microbiology Research · doi:10.3390/microbiolres14030093
Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses
Wu, C.-Y., Tseng, Y.-C., Kao, S.-E., Wu, L., Hou, J.-T., Yang, Y., Hsiao, P., & Chen, J.-R. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105759
B cell responses to SARS-CoV-2
Zaidi, A. K., Bajpai, S., & Dehgani‐Mobaraki, P. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.11.006
Prevalência e reatividade cruzada entre SARS-CoV-2 e HCoVs endêmicos
Lima, A. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2023.tde-07122023-181214
Post-vaccinal reactions following vaccination with the COVID-19 vaccine after first and second dose
Stoeva, V., Rosen, M., Pencheva, B., & Antoineta, M. (2024) · Journal of Vaccines and Immunology · doi:10.17352/jvi.000060
Comparison of NADAL COVID IgG/IgM rapid test and DiaSorin Liaison SARS-CoV-2 S1/S2 IgG assay across different blood sources and substrates
Dasari, H., Bourassa, C., Renaud, C., Tremblay, C. L., & Ducharme, F. M. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.03350-24
SARS-CoV-2 and HCoV IgG Antibodies in the Breast Milk of a Postpartum SARS-CoV-2 Patient Following Bamlanivimab Administration: A Case Report
Tanunliong, G., Condin, C., Márquez, A. C., Li, S., Binning, N., Gibson, M., Griffiths, B., Wright, A. J., Money, D., Krajden, M., et al. (2025) · COVID · doi:10.3390/covid5080123
A funnel approach to enable analyses of epitope-specific human CD4 T cells specific for influenza and SARS-CoV-2
Richards, K. A., Mettelman, R. C., Trombley, K., Eismann, M., Allen, E. K., Scott, Z. B., Joachimiak, A., Schultz‐Cherry, S., Chaves, F. A., Thomas, P. G., et al. (2026) · mBio · doi:10.1128/mbio.00449-26
Self-citation
Serological evaluation of coronavirus IgA and IgG antibodies in a repeated cross-sectional cohort of unvaccinated and vaccinated pregnant individuals over three months following SARS-CoV-2 infection
Tanunliong, G., Márquez, A. C., Sbihi, H., Pidduck, T., Chang, Y. X., Li, F. F., Luk, D., Forward, L., McClymont, E., Elwood, C. N., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02167-25
Additional file 3 of Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol
Muñoz, F. M., Beigi, R. H., Posavad, C. M., Richardson, B. A., Chu, H. Y., Bok, K., Campbell, J., Cardemil, C. V., DeFranco, E., Frenck, R. W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19759322
Additional file 1 of Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol
Muñoz, F. M., Beigi, R. H., Posavad, C. M., Richardson, B. A., Chu, H. Y., Bok, K., Campbell, J., Cardemil, C. V., DeFranco, E., Frenck, R. W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19759316

Authors: Nguyen-Contant, P., Embong, A. K., Kanagaiah, P., Chaves, F. A., Yang, H., Branche, A. R., Topham, D. J., & Sangster, M. Y.
Affiliations: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA
University of Rochester Medicine (US)
Corresponding author: Sangster, Mark Y.
ORCID: Embong, A. Karim
Kanagaiah, Preshetha
Chaves, Francisco A.
Yang, Hongmei
Branche, Angela R.
Topham, David J.
Sangster, Mark Y.
Venue: mBio
Publisher: American Society for Microbiology
Published: 2020-10-27
Volume: 11
Issue: 5
ISSN: 2150-7511 (ISSN-L)
2161-2129
DOI: 10.1128/mbio.01991-20
PMC: PMC7520599
OpenAlex: W3087903445
Cited by: 204
References: 35
Citations by year: 2026: 3 · 2025: 13 · 2024: 16 · 2023: 29 · 2022: 60 · 2021: 75 · 2020: 8
FWCI: 5.64
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
journals.asm.org/non-commercial-tdm-license (tdm)
Locations: mBio (publishedVersion, cc-by)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400005C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, COVID-19 pandemic, S protein, S2 subunit, receptor binding domain, memory B cells, IgG, antibody response, pre-existing immunity, reinfection, cross-reactive antibodies, coronavirus
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, Adult, Antibodies, Viral, B-Lymphocytes, Convalescence, Cross Reactions, Female, Humans, Immunoglobulin G, Immunologic Memory, Male, Middle Aged, Phosphoproteins, Pneumonia, Viral, Coronavirus Infections, Nucleocapsid Proteins, Protein Subunits, Protein Interaction Domains and Motifs, Pandemics, Healthy Volunteers, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks